Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 7/20 | 0.46 |
| ▸ | MAOA | P21397 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | AOC1 | P19801 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6297386 | 0.78 | MAOB (0.49) | PKMMAOBMAOAMEN1KMT2A | |
| SCHEMBL11713041 | 0.77 | MEN1 (0.69) | MAOBMAOAMEN1KMT2AHSP90AA1 | |
| SCHEMBL27277013 | 0.67 | PKM (1.00) | PKMMAOBMAOAAOC1 | |
| SCHEMBL6292980 | 0.64 | MEN1 (0.45) | PKMMAOBMAOAMEN1KMT2A | |
| SCHEMBL6298325 | 0.64 | ESD (0.60) | MAOBMAOAMEN1KMT2AHSP90AA1 | |
| SCHEMBL6294160 | 0.63 | ESD (0.58) | PKMMAOBMAOAMEN1KMT2A | |
| SCHEMBL23297 | 0.63 | PDPK1 (0.53) | HSP90AA1 | |
| SCHEMBL29658188 | 0.63 | PDPK1 (0.53) | HSP90AA1 | |
| SCHEMBL6294300 | 0.63 | ESD (0.63) | MAOBMAOAMEN1KMT2AHSP90AA1 | |
| SCHEMBL5945842 | 0.62 | PDPK1 (0.52) | HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030083351-A1 | Medicinal uses of dihydropyrazoles | THE PROCTER & GAMBLE COMPANY | 2003-05-01 | — | — | US | claimed |
| WO-2002089799-A2 | USE OF DIHYDROPYRAZOLES TO INCREASE ERYTHROPOIETIN AND VASCULARI ZATION | THE PROCTER & GAMBLE COMPANY (US) | 2002-11-14 | — | — | WO | claimed |
| US-20050090532-A1 | Medicinal uses of dihydropyrazoles | THE PROCTER & GAMBLE COMPANY | 2005-04-28 | — | — | US | disclosed |
| US-6878729-B2 | Medicinal uses of dihydropyrazoles | THE PROCTER & GAMBLE COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20030083351-A1 | Medicinal uses of dihydropyrazoles | THE PROCTER & GAMBLE COMPANY | 2003-05-01 | — | — | US | disclosed |
| WO-2002089799-A2 | USE OF DIHYDROPYRAZOLES TO INCREASE ERYTHROPOIETIN AND VASCULARI ZATION | THE PROCTER & GAMBLE COMPANY (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090532-A1 | Medicinal uses of dihydropyrazoles | EPOR, VEGFA, FLT4 | PKM 732/4885MAOB 437/4885MAOA 816/4885 |
| US-20030083351-A1 | Medicinal uses of dihydropyrazoles | EPOR, VEGFA, TEK | PKM 777/4885MAOB 716/4885MAOA 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.